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Background
The effect of MK-7243 (2800 BAU/75,000 SQ [~15 µg
of Phleum pratense p 5], Merck/ALK-Abelló), a sublin-
gual Timothy grass immunotherapy tablet, has been
evaluated in several randomized, placebo-controlled,
double-blind trials; three of these trials were conducted
in adults and children in North America (the United
States and Canada) who have allergic rhinitis with or
without conjunctivitis (AR/C). We conducted a post-hoc
analysis to investigate the effect of MK-7243 in Cana-
dian subpopulations.
Methods
Data from Canadian subjects from the three trials were
used in this investigation: P05238 (adults ≥18 y; pollen
season: 2009); P05239 (children 5−<18 y; pollen sea-
son=2009); and P08067 (adults ≥65 y and children
5−<18 y; pollen season: 2012). Trial data from the same
grass pollen seasons (GPS) were pooled. Subjects
received once-daily MK-7243 or placebo starting ≥12 wk
before and continuing throughout the GPS, for a mean
total of ≥23 wk. The therapeutic effect of MK-7243 was
evaluated for rhinoconjunctivitis symptoms and sympto-
matic medication use, measured as a total combined
score (TCS=daily-symptom score [DSS; max=18]+daily-
medication score [DMS; max=36]) averaged over the
entire GPS. Safety was assessed by monitoring adverse
events (AEs).
Results
Canadian subjects taking MK-7243 (n=42) in the pooled
adult-pediatric 2009 trials showed a 38% mean TCS
reduction versus placebo (n=54; −2.06 difference [95%
CI: −3.72, −0.39]; 3.32 vs. 5.37). Canadian subjects tak-
ing MK-7243 (n=122) in the adult-pediatric 2012 trial
showed a 33% mean TCS reduction relative to placebo
(n=122; −1.62 difference [95% CI: −2.54, −0.71]; 3.34 vs.
4.96). Approximately 90% of treatment-related AEs were
mild or moderate in severity. No serious or life-threa-
tening treatment-related AEs occurred.
Conclusions
MK-7243 Timothy grass sublingual tablet significantly
improved AR/C induced by Timothy grass pollen in
Canadian adults and children 5 y and older. Similar effi-
cacy and safety results were obtained for the overall
populations of the three trials.
Trial registration
ClinicalTrials.gov Identifiers: NCT00562159; NCT00
550550; NCT01385371.
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